The Cigna Group is consolidating its board committee structure, dissolving its standalone compliance committee and redistributing oversight responsibilities across other committees, effective Jan. 1.
The board approved the changes in late October, according to an SEC filing. The restructuring follows Cigna’s sale of its Medicare Advantage, individual Medicare prescription drug plans and supplemental benefits businesses earlier this year, which reduced the scope of compliance oversight needed.
The company’s audit committee will be renamed the audit and compliance committee and assume responsibility for enterprise compliance matters. The corporate governance committee will oversee the company’s ethics program and public clinical reporting. The full board will handle clinical compliance oversight, including patient experience and satisfaction.
The finance committee will become the finance and technology committee, taking on consolidated oversight of technology strategy, information security, business continuity and artificial intelligence.
The people resources committee’s responsibilities remain unchanged.
